Minerva Imaging

Last week, our Department Manager for Molecular and Cellular Biology, Sebastian Gnosa, presented a poster on the establishment and evaluation of radioresistant models from patient derived tissue and how they can be used to screen radiosensitizing agents at the ENA symposium in Barcelona. The ENA symposium, also known as the triple meeting, is organized by EORTC - European Organisation for Research and Treatment of Cancer, National Cancer Institute (NCI) and American Association for Cancer Research.   It was great to discuss the latest developments on molecular targets and cancer therapeutics with peer scientists and drug developers. Interested in learning more about the poster or how we can support your oncology programs? Contact us today via https://lnkd.in/gyGpdVB   #CancerResearch #Oncology #drugdevelopment #ENASymp24

This month Atley Solutions installed their first commercial C100 module at Minerva Imaging, fostering availability of Astatine-211 (At-211) based radiopharmaceuticals. The Atley C100 module can be used for both purification of At-211 from irradiated cyclotron targets and for automated synthesis of At-211 labelled radiopharmaceuticals. At-211 has unique properties with its short half-life, favorable decay chain, and scalable production.  Carsten Haagen Nielsen, CEO and co-founder at Minerva Imaging commented: “At-211 holds strong promises as a payload for targeted radionuclide therapy, contributing to the development of medicines for patients with an unmet need. With the installation of the commercial version of the C100 module, Minerva Imaging has all the capabilities in-house to support our collaborators in studies utilizing At-211, from preclinical target validation to early clinical work.”   Read the full press release on our website: https://lnkd.in/d_K7ZSiu   #Astatine211 #At211 #radiopharmaceuticals #targetedtherapy #oncology 

Day 3 of the European Association of Nuclear Medicine (EANM) annual meeting in Hamburg. Drop by our booth F05 in the foyer to learn more about our fully integrated CRO and CDMO facility specialized in targeted radionuclide therapy and molecular imaging. #molecularimaging #radiopharmaceuticals #theranostics #nuclearmedicine #targetedtherapy #oncology #EANM24

Good morning Hamburg, rise and shine! We are ready to run into EANM and look forward to meet with scientists and industry leaders and to discuss and share insights on the latest developments in the field of nuclear medicine. Drop by our booth F05 in the foyer to learn more about our fully integrated CRO and CDMO facility specialized in targeted radionuclide therapy and molecular imaging. #molecularimaging #radiopharmaceuticals #theranostics #nuclearmedicine #targetedtherapy #oncology #EANM24

Join us at the 36th ENA symposium on molecular targets and cancer therapeutics, 23-25 October in Barcelona, Spain. The symposium, also known as the triple meeting, is organized by EORTC - European Organisation for Research and Treatment of Cancer, National Cancer Institute (NCI) and American Association for Cancer Research. Our Department Manager for Molecular and Cellular Biology, Sebastian Gnosa, will present a poster about the establishment and evaluation of radioresistant models from patient derived tissue and their application to screen for radiosensitizing agents. Poster session will take place Thursday, October 24th, 09:00 - 17:30 in the Exhibition Hall, Session code: 480, poster 272.   Interested booking a meeting with Sebastian to learn more about our advanced preclinical oncology models? Contact us today via https://lnkd.in/gyGpdVB   #CancerResearch #Oncology #drugdevelopment #ENASymp24

Minerva Imaging is proud to be part of the Thera4Care project, which has recently received funding from the Innovative Health Initiative (IHI). This large consortium brings together leading academic radiotheranostic centers, industry experts, medical societies, and patient advocates to revolutionize precision oncology and establish Europe as a global leader in theranostics. In the next five years, we will join forces with 28 partners to develop, implement, and share standardized, scalable methods for efficiently producing and administering radiotheranostic solutions. Being part of the consortium, Minerva aims to increase medical knowledge and contribute to the development of medicines for patients with an unmet need. We are excited to be part of this unique collaboration to transform cancer care and advance precision medicine for patients. Read more about the consortium on our website: https://lnkd.in/d9PpxVWF #Thera4Care #IHI #PrecisionOncology #Theranostics #HealthcareInnovation

Last week, Minerva Imaging attended the career fair at Københavns Professionshøjskole for laboratory technicians. Career fairs serve as a vital bridge between education and the professional world, helping students to take meaningful steps toward their future careers. It was a great opportunity to meet the students, ask questions, share job openings, and make connections leading to future employment. We had a great time and will be back next year!

In 2 weeks, we are heading to Hamburg for the European Association of Nuclear Medicine (EANM) Annual meeting. You can meet us at booth F05 to learn more about our fully integrated CRO and CDMO facility specialized in targeted radionuclide therapy and molecular imaging. Minerva proudly collaborated on different abstract to be presented at the EANM, more information can be found on our website including a link to schedule a meeting with us at the EANM: https://lnkd.in/d9b3qkAU We are looking very much forward to meet with key scientists and industry leaders and to discuss and share insights on the latest developments in the field of nuclear medicine. #molecularimaging #radiopharmaceuticals #theranostics, #nuclearmedicine #targetedtherapy #oncology #EANM24

Minerva Imaging is very proud to be part of the new Innovative Health Initiative (IHI) Joint Undertaking (IHI JU) Thera4Care, a public-private initiative aiming to revolutionize precision oncology and strengthen theranostics within EU. Stay tuned for more updates the coming days. #Thera4Care #IHI #PrecisionOncology #Theranostics #HealthcareInnovation

This week marks Nuclear Medicine & Molecular Imaging Week designated by the Society of Nuclear Medicine and Molecular Imaging (SNMMI). We are excited to engage with the nuclear medicine and molecular imaging community to raise awareness and support for this dynamic and crucial field. At Minerva Imaging, we are proud to continue over two decades of dedicated research in the field. Our mission is to promote innovation by collaborating with our partners to advance new treatment approaches for patients. We are committed to developing targeted radionuclide therapies and imaging modalities to pave the way for breakthroughs in therapeutics and diagnostics. Contact us to discuss how our molecular imaging services can be incorporated into your drug development programs: https://lnkd.in/dTkvqRqY #NUCMEDWEEK #NuclearMedicineWeek #NMW24 #molecularimaging #radiopharmaceuticals #targetedradionulidetherapy #theragnostics